Can We Really Accelerate and Enhance the Selective Serotonin Reuptake Inhibitor Antidepressant Effect?: A Randomized Clinical Trial and a Meta-Analysis of Pindolol in Nonresistant Depression
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Since depression entails not only dramatic personal disruption but also a huge amount of medical and socioeconomic burden, slowness of antidepressant action and difficulties to attain remission are entangled issues to be solved. Given the controversial previous findings with enhancing strategies such as pindolol, we examined whether the speed of selective serotonin reuptake inhibitor (SSRI) action can be truly accelerated with optimized pindolol dosage. Additionally, we aimed at elucidating whether pindolol benefits emerge, particularly in a population with nonresistant depression. METHOD: Thirty outpatients with major depressive disorder (DSM-IV criteria) recruited between December 2002 and November 2005 were randomly assigned to receive citalopram + pindolol (5 mg tid) or citalopram + placebo for 6 weeks in a double-blind randomized clinical trial. A meta-analysis of randomized controlled trials of pindolol augmentation in patients with nonresistant depression was also performed. Outcome criteria were based on the 17-item Hamilton Depression Rating Scale. For the meta-analysis, efficacy was assessed by the number of treatment responders at 2 weeks and 4-6 weeks. RESULTS: Clinical trial outcomes: Repeated-measures analysis of variance showed a significant group-by-time interaction (P = .01). Cumulative percentage showed a trend for sustained response (odds ratio [OR] = 2.09; 95% CI, 0.914-4.780; P = .08) and a well-defined increased likelihood of sustaining remission (OR = 5.00; 95% CI, 1.191-20.989; P = .03) in pindolol receivers. Median survival time until first response was 65% less in the pindolol group (22 days vs 30 days; P = .03). The negative binomial regression model yielded different rates of response per person-day for pindolol and placebo groups (7.6% vs 4.7%, respectively; P = .03). Meta-analysis: Outcome favored pindolol at 2 weeks' time (relative risk [RR] = 1.68; 95% CI, 1.18-2.39; P = .004) and also at 4-6 weeks' time (RR = 1.11; 95% CI, 1.02-1.20; P = .02). CONCLUSIONS: Present findings represent further evidence of the acceleration and enhancement of efficacy with pindolol administered together with SSRIs, displaying a quicker and more pronounced decrease of symptoms in patients with nonresistant major depressive disorder. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00931775.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“Placebo controlled studies of augmentation with buspirone or pindolol have been unconvincing and hence these are not recommended (Lam et al., 2009; Martiny et al., 2012; Portella et al., 2011).”
BackgroundThe Forced Swim Test as a Model of Depressive-like Behavior
Yankelevitch-Yahav, R., Franko, M., Huly, A., & Doron, R. (2015) · Journal of Visualized Experiments · doi:10.3791/52587 · Cited by 754
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“Combination of an SSRI and pindolol (a 5-HT 1A /beta-adrenoceptor antagonist) markedly accelerated the speed of the antidepressant response in previously untreated patients (Artigas et al. 1996; Portella et al. 2011).”
BackgroundCelada, P., Bortolozzi, A., & Artigas, F. (2013) · CNS Drugs · doi:10.1007/s40263-013-0071-0 · Cited by 323
Self-citationCitalopram versus other anti-depressive agents for depression
Cipriani, A., Purgato, M., Furukawa, T. A., Trespidi, C., Imperadore, G., Signoretti, A., Churchill, R., Watanabe, N., & Barbui, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006534.pub2 · Cited by 311
Barnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
Scorza, M., Lladó‐Pelfort, L., Oller, S., Cortés, R., Puigdemont, D., Portella, M., Pérez‐Egea, R., Alvarez, E., Celada, P., Pérez, V, et al. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01770.x · Cited by 46
Self-citationMolecular and Cellular Mechanisms of Antidepressant Action
Sharp, T. (2012) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2012_216 · Cited by 36
Liu, Y., Zhou, X., Zhu, D., Chen, J., Qin, B., Zhang, Y., Wang, X., Yang, D., Meng, H., Luo, Q., et al. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2465 · Cited by 26
“…1996; Berman et al., 1997; Perez et al., 1997; Tome et al., 1997; Zanardi et al., 1997; Bordet et al., 1998; Zanardi et al., 1998; Berman et al., 1999; Perez et al., 1999; Portella et al., 2011), culminating in the two positive meta-analyses (Ballesteros and Callado, 2004; Portella et al., 2011).”
BackgroundInfluentialShi, L., Wang, J., Xu, S., & Lu, Y. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s122085 · Cited by 13
“SSRI is a wellestablished first-line antidepressant,(7) and its antidepressant efficacy may be enhanced by the 5-HT 1A receptor partial agonist working to improve the onset of therapeutic action.(8) This unique dual modulation of serotonin neurotransmission by vilazodone correspondence: Yunrong lu Department of Psychi…”
Background
Metadata
- Authors
- Portella, M. J., de Diego-Adeliño, J., Ballesteros, J., Puigdemont, D., Oller, S., Santos, B., Álvarez, E., Artigas, F., & Pérez, V.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-10-19
- Volume
- 72
- Issue
- 07
- Pages
- 962-969
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1987837679
- Cited by
- 63
- References
- 0
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.